首页> 外文OA文献 >Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

【2h】

Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

机译：使用肿瘤浸润的CD8至FoxP3淋巴细胞比例在预测治疗响应与Pertuzumab，Trastuzumab和Docetaxel进行高级Her2阳性乳腺癌的治疗反应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Koji Takada; Shinichiro Kashiwagi; Wataru Goto; Yuka Asano; Katsuyuki Takahashi; Tsutomu Takashima; Shuhei Tomita; Masahiko Ohsawa; Kosei Hirakawa; Masaichi Ohira;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer [J] . Koji Takada, Shinichiro Kashiwagi, Wataru Goto, Journal of Translational Medicine . 2018,第1期

机译：肿瘤浸润CD8与FOXP3淋巴细胞比率在预测帕妥珠单抗，曲妥珠单抗和多西他赛联合治疗晚期HER2阳性乳腺癌的治疗反应中的应用
2. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer [J] . Takada Koji, Kashiwagi Shinichiro, Goto Wataru, Anticancer Research: International Journal of Cancer Research and Treatment . 2018,第4期

机译：用Pertuzumab，Trastuzumab和Docetaxel进行高级Her2阳性乳腺癌的组合治疗中的家庭（HER1-4）表达作为生物标志物
3. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer [J] . Takada Koji, Kashiwagi Shinichiro, Goto Wataru, Anticancer Research: International Journal of Cancer Research and Treatment . 2018,第4期

机译：用Pertuzumab，Trastuzumab和Docetaxel进行高级Her2阳性乳腺癌的组合治疗中的家庭（HER1-4）表达作为生物标志物
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab trastuzumab and docetaxel for advanced HER2-positive breast cancer [O] . Koji Takada, Shinichiro Kashiwagi, Wataru Goto, 2018

机译：肿瘤浸润CD8与FOXP3淋巴细胞比率在预测帕妥珠单抗曲妥珠单抗和多西他赛联合治疗晚期HER2阳性乳腺癌的治疗反应中的应用
7. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer [O] . 2018

机译：用Pertuzumab，Trastuzumab和Docetaxel进行高级HER2阳性乳腺癌的组合治疗中的家庭（HER1-4）表达作为生物标志物

Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅